UBS Group Reiterates Neutral Rating for Avantor (NYSE:AVTR)

Avantor (NYSE:AVTR)‘s stock had its “neutral” rating restated by stock analysts at UBS Group in a research note issued to investors on Friday, Marketbeat reports. They presently have a $25.00 price target on the stock, down from their previous price target of $29.00. UBS Group’s target price would indicate a potential upside of 12.91% from the stock’s previous close.

Several other research firms have also weighed in on AVTR. Royal Bank of Canada reissued an “outperform” rating and set a $34.00 price target on shares of Avantor in a research report on Thursday, September 26th. Barclays reduced their target price on Avantor from $28.00 to $25.00 and set an “overweight” rating on the stock in a report on Friday, October 25th. Robert W. Baird cut their target price on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a research report on Monday, October 28th. Finally, Wells Fargo & Company reduced their target price on Avantor from $30.00 to $28.00 and set an “overweight” rating on the stock in a report on Monday, October 28th. Three research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $27.38.

Avantor Price Performance

NYSE AVTR opened at $22.14 on Friday. Avantor has a 52 week low of $19.59 and a 52 week high of $28.00. The stock has a market cap of $15.07 billion, a price-to-earnings ratio of 48.13, a price-to-earnings-growth ratio of 3.42 and a beta of 1.28. The company has a 50-day moving average price of $21.45 and a two-hundred day moving average price of $23.35. The company has a current ratio of 1.54, a quick ratio of 1.06 and a debt-to-equity ratio of 0.84.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of AVTR. Envestnet Asset Management Inc. raised its stake in shares of Avantor by 1.7% during the second quarter. Envestnet Asset Management Inc. now owns 1,097,671 shares of the company’s stock valued at $23,271,000 after acquiring an additional 18,672 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Avantor by 8.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 4,434,195 shares of the company’s stock valued at $94,018,000 after buying an additional 350,247 shares during the last quarter. Vanguard Personalized Indexing Management LLC increased its position in shares of Avantor by 4.6% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 25,440 shares of the company’s stock valued at $539,000 after purchasing an additional 1,119 shares during the last quarter. Seven Eight Capital LP purchased a new stake in Avantor in the 2nd quarter worth about $642,000. Finally, First Eagle Investment Management LLC lifted its position in shares of Avantor by 16.4% during the second quarter. First Eagle Investment Management LLC now owns 18,482 shares of the company’s stock worth $392,000 after acquiring an additional 2,600 shares in the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.